Track market-moving stories before they get noisy

Salt Lake City, UT, April 30, 2026 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical-stage TechBio company decoding biology to radically improve lives, today announced that Chris Gibson, Ph.D., will complete his current term through June 2026 and does not intend to seek re-election to the Company’s Board of Directors.  

“I greatly appreciated Chris’s partnership during my transition into the CEO role at Recursion and am pleased that he will remain an advisor to the company moving forward,” said Najat Khan, Ph.D., Chief Executive Officer and President of Recursion. “We remain focused on continuity and long-term value creation at Recursion. With a strong foundation and team in place, I’m excited about what we will deliver to shareholders and patients - advancing both our internal and partnered pipeline while translating our AI-powered platform into meaningful therapeutic impact.”

“I’d like to thank Chris for his vision in founding Recursion and for his meaningful contributions to the field,” said Rob Hershberg, M.D., Ph.D., Vice-Chair of the Board and Lead Independent Director. “Chris has played an important role in supporting our evolution over the last several months as an advisor, founder, and leader, and we are deeply grateful for his partnership and guidance.”

“Being a founder of Recursion and participating in building the company with an amazing team has been one of the most rewarding journeys that I could have imagined,” said Chris Gibson, Ph.D., Founder and Chair (advisor) of Recursion. “I look forward to watching Recursion flourish under Najat’s leadership and am excited to continue my connection to the company as a strategic advisor. I am excited about Recursion’s future and, as always, will be cheering for Recursion with a full heart.”

About Recursion

Recursion (NASDAQ: RXRX) is a clinical-stage TechBio company decoding biology to radically improve lives. Recursion is advancing a portfolio of differentiated investigational medicines across its wholly owned and partnered pipeline in oncology, rare disease, neuroscience, immunology, and other therapeutic areas with significant unmet need. Enabling its mission is the Recursion OS, an AI-native, end-to-end drug discovery and development platform integrating biology, chemistry, and clinical development into a unified intelligence system. Powered by proprietary multimodal data, purpose-built AI models, and bilingual teams fluent in both science and AI, the Recursion OS is designed to translate complex science into medicines that matter — faster, better, and at scale — for patients who are waiting.

Recursion’s platform infrastructure is anchored in Salt Lake City, Utah and Milton Park, Oxfordshire, where its automated biology and chemistry laboratories generate proprietary data at industrial scale. Recursion also maintains offices in New York, Montréal, and London, three global hubs for talent and leadership at the intersection of AI and scientific innovation. Learn more at www.recursion.com, or connect on X and LinkedIn.

Forward-Looking Statements

This press release contains forward-looking statements, including, without limitation, statements regarding Recursion’s future plans, strategy, growth opportunities, leadership, and ability to advance its mission, platform, pipeline, and partnerships. These forward-looking statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These and other risks are described in Recursion’s filings with the U.S. Securities and Exchange Commission. Recursion undertakes no obligation to update any forward-looking statements except as required by law.

SALT LAKE CITY, May 06, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, today reported business updates highlighting strong continued pipeline execution, clinical progress and platform advancement, as well as financial results for its first quarter ended March 31, 2026.

Recursion Pharmaceuticals, Inc. (RXRX) Q1 2026 Earnings Call Transcript

• Recursion Pharmaceuticals shares are retreating from recent levels. Why is RXRX stock falling?

The company is scheduled to provide an update about the FDA decision in the second half of the year. And, there is potential upside to the stock, according to Needham.

The Recursion Pharmaceuticals Analyst: Analyst Gil Blum maintained a Buy rating and price target of $8.

The Recursion Pharmaceuticals Thesis: The company reported non-GAAP operating expenditure of $85 million for the first quarter, representing a decline of around 30% year-on-year, with a fiscal year cash burn guidance of less than $390 million, Blum said in the note.

Check out other analyst stock ratings.

The update on the pivotal trial design for REC-4881 will be the "next value driver" for Recursion Pharmaceuticals, the analyst stated.

"Given the lack of regulatory precedent in FAP, Recursion intends to focus on natural history data, identification of appropriate patient populations, optimizing dose escalation, and defining clinically meaningful endpoints," Blum wrote.

The company intends to leverage its AI-enabled clinical platform to support registrational planning and accelerate enrolment, he added.

"Recursion also reported initial REC-1245 safety and PK data across four dose cohorts, showing mostly low-grade AEs (adverse events)," the analyst further noted.

RXRX Price Action: Shares of Recursion Pharmaceuticals had declined by 3.85% to $3.30 at the time of publication on Thursday.

Market News and Data brought to you by Benzinga APIs

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

To add Benzinga News as your preferred source on Google, click here.

SALT LAKE CITY, May 19, 2026 (GLOBE NEWSWIRE) -- Altitude Lab, the platform-first biotech-startup accelerator founded by Recursion (NASDAQ: RXRX), announced today that its portfolio companies have collectively raised more than $205 million in early-stage funding since the program's launch in 2020. The milestone reflects a portfolio of companies advancing into clinical trials, signing deals with global pharma, and commercializing platform technologies reshaping the boundaries of early-stage biotech despite this difficult funding climate.

Dr. Joshua Schiffman, CEO/Co-founder of Peel Therapeutics, credits their success to initial support from Altitude Lab, "With Altitude Lab serving as our biotech basecamp, we now have become a clinical stage biotech with encouraging initial results and multiple phase trials both in Utah and throughout the country."

2025 proved pivotal for Altitude Lab's startups, with inaugural cohort alumni Peel Therapeutics and Rebel Medicine raising Series A rounds to accelerate clinical development. These companies continue to build the backbone of Salt Lake City's maturing biotech ecosystem and define the Mountain West region on a national stage.

Portfolio Momentum & Milestones:

Peel Therapeutics: Closed a fully subscribed $20 million Series A. Lead asset PEEL-224, an optimized TOP1 inhibitor, demonstrated a 68% disease control rate with limited GI toxicity in heavily pre-treated solid tumor patients (N=47) in its Phase 1A trial. Proceeds from the Series A will support the company's ongoing Phase 1B/2 clinical development in metastatic colorectal cancer and pediatric solid tumors, as well as advance Peel’s broader oncology pipeline.

Rebel Medicine: Closed a $7.5M Series A led by Crocker Ventures and received FDA IND clearance for Alevatrix, its long-acting bupivacaine reformulation designed to provide up to 72 hours of non-opioid pain relief. Rebel is running its first-in-human Phase 2 trial evaluating Alevatrix as an opioid-sparing therapy.

Leash Bio: Signed a multi-target agreement with Monte Rosa Therapeutics to accelerate discovery of degraders for difficult-to-drug targets. Leash's platform had identified tractable material for over 500 targets prior to the partnership, enabling compounds to reach Monte Rosa's team in a fraction of the typical timeline.

Intactis Bio: Raised $250K from Nucleus Fund, post-investment from RPV, and achieved a landmark milestone: lab-grown neurons derived from iPSCs successfully demonstrated encoding and decoding of language and math operations, with continuous learning during inference, a structural advantage over GPUs.

Sethera Therapeutics: Entered award negotiations for a significant and highly competitive CDMRP Breast Cancer Research Program Breakthrough Award. Sethera continued strengthening its Scientific Advisory Board with the addition of a Nobel Laureate in Physiology and/or Medicine, joining members Jeffery W. Kelly (Scripps Research), Alexander M. Klibanov (MIT), and Dr. Robert Langer (MIT).

3Helix: Announced a partnership with BASF, successfully launching NeoHelix™ Regenerate, the first precision peptide inspired by 3Helix's proprietary collagen-hybridizing peptide (CHP) technology. In clinical studies, the ingredient demonstrated a 41% reduction in damaged collagen and a 65% increase in hyaluronic acid levels after 56 days.

Calycia Biosciences: A University of Utah spin-out and part of Altitude Lab’s new cohort, won Altitude Lab's 2026 Demo Day and secured $400,000 in pre-seed funding from University of Utah Ventures (operated by EPIC Ventures) and Cumming Foundation.

Leadership Transition

Altitude Lab has appointed Kapil Sharma as Interim Executive Director. Sharma has spent four years expanding the organization's national visibility and network of investors and strategic partners to more than 200 firms.

"Our mission remains unchanged: to build a new breed of biotech companies and a nationally interconnected ecosystem, while strengthening Salt Lake City's position as an upcoming biotech hub," said Sharma.

Chandana Haque, co-founder and former Executive Director, will continue to support the organization as a board member.

About Altitude Lab

Altitude Lab is developing a new generation of biotech founders to seed the next cycle of health care innovation. Headquartered in Salt Lake City, Utah, Altitude Lab is a Recursion startup accelerator focused on launching early-stage life science companies, with an emphasis in TechBio and platform-based technology commercialization. The Recursion Charitable Foundation, DBA Altitude Lab, operates as a 501(c)(3) nonprofit and is a large contributor to Utah's BioHive.

Learn more at altitudelab.org or connect on X and LinkedIn.

Salt Lake City, UT, June 02, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical-stage TechBio company decoding biology to radically improve lives, today announced its participation in an upcoming investor conference:

Goldman Sachs 47th Annual Global Healthcare Conference — Tuesday, June 9, 2026 Webcasts may be found in the events section of the Recursion Investor Relations website at ir.recursion.com. 
About Recursion
Recursion (NASDAQ: RXRX) is a clinical-stage TechBio company decoding biology to radically improve lives. Recursion is advancing a portfolio of differentiated investigational medicines across its wholly owned and partnered pipeline in oncology, rare disease, neuroscience, immunology, and other therapeutic areas with significant unmet need. Enabling its mission is the Recursion OS, an AI-native, end-to-end drug discovery and development platform integrating biology, chemistry, and clinical development into a unified intelligence system. Powered by proprietary multimodal data, purpose-built AI models, and bilingual teams fluent in both science and AI, the Recursion OS is designed to translate complex science into medicines that matter — faster, better, and at scale — for patients who are waiting.
Recursion’s platform infrastructure is anchored in Salt Lake City, Utah and Milton Park, Oxfordshire, where its automated biology and chemistry laboratories generate proprietary data at industrial scale. Recursion also maintains offices in New York, Montréal, and London, three global hubs for talent and leadership at the intersection of AI and scientific innovation. Learn more at www.recursion.com, or connect on X and LinkedIn.
Media Contact
[email protected]
Investor Contact
[email protected]

Recursion Pharmaceuticals, Inc. (RXRX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

9.22K Followers

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Neogen (NASDAQ: NEOG - Get Free Report) and Sunny Optical Technology (Group) (OTCMKTS:SNPTF - Get Free Report) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, earnings and analyst recommendations. Profitability This table compares Neogen and Sunny

-

LANSING, Mich.--(BUSINESS WIRE)--Neogen® Corporation (NASDAQ: NEOG) will issue its third-quarter earnings release before the opening of the market on Thursday, April 9, 2026. Executives from the company will host a webcast and conference call later that morning, beginning at 8:00 a.m. Eastern time. During the call, Neogen management will provide a financial overview and business update of the company’s performance for the third-quarter of fiscal year 2026.

The conference call can be accessed by dialing:
Toll-Free - North America: 1-800-549-8228
International: (+1) 646-564-2877
Conference ID: 70064#

The live webcast can be accessed through Neogen’s Investor Relations webpage, neogen.com/investor-relations, under the “Events & Presentations” subheading.

A replay of the conference call and webcast will be available shortly following the conclusion of the call and can be accessed by dialing:
Toll-Free - North America: (1) 888-660-6264
International: (+1) 646-517-3975
Passcode: 70064 #

It will also be available on Neogen’s Investor Relations website at neogen.com/investor-relations.

About Neogen

Neogen Corporation is committed to fueling a brighter future for global food security through the advancement of human and animal well-being. Harnessing the power of science and technology, Neogen has developed comprehensive solutions spanning the Food Safety, Livestock, and Pet Health & Wellness markets. A world leader in these fields, Neogen has a presence in over 140 countries with a dedicated network of scientists and technical experts focused on delivering optimized products and technology for its customers.

More News From Neogen Corporation

Back to Newsroom

In its upcoming report, Neogen (NEOG - Free Report) is predicted by Wall Street analysts to post quarterly earnings of $0.04 per share, reflecting a decline of 60% compared to the same period last year. Revenues are forecasted to be $204.46 million, representing a year-over-year decrease of 7.5%.

The consensus EPS estimate for the quarter has undergone a downward revision of 8.3% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.

Ahead of a company's earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. These revisions serve as a noteworthy factor in predicting potential investor reactions to the stock. Numerous empirical studies consistently demonstrate a strong relationship between trends in earnings estimate revision and the short-term price performance of a stock.

While investors usually depend on consensus earnings and revenue estimates to assess the business performance for the quarter, delving into analysts' forecasts for certain key metrics often provides a more comprehensive understanding.

With that in mind, let's delve into the average projections of some Neogen metrics that are commonly tracked and projected by analysts on Wall Street.

Analysts predict that the 'Revenues- Animal Safety' will reach $56.02 million. The estimate indicates a change of -17.9% from the prior-year quarter.

It is projected by analysts that the 'Revenues- Food Safety' will reach $148.11 million. The estimate indicates a change of -3% from the prior-year quarter.

According to the collective judgment of analysts, 'Revenues- Food Safety- Indicator Testing, Culture Media & Other' should come in at $81.18 million. The estimate points to a change of +4.4% from the year-ago quarter.

Analysts' assessment points toward 'Revenues- Animal Safety- Veterinary Instruments & Disposables' reaching $15.38 million. The estimate indicates a year-over-year change of -0.2%.

Analysts expect 'Revenues- Animal Safety- Animal Care & Other' to come in at $9.61 million. The estimate suggests a change of -8.5% year over year.

The combined assessment of analysts suggests that 'Revenues- Food Safety- Natural Toxins & Allergens' will likely reach $17.65 million. The estimate indicates a year-over-year change of +0.3%.

The average prediction of analysts places 'Revenues- Animal Safety- Genomics Services' at $3.34 million. The estimate suggests a change of -80.4% year over year.

The consensus among analysts is that 'Revenues- Food Safety- Genomics Services' will reach $11.34 million. The estimate suggests a change of +99% year over year.

The consensus estimate for 'Revenues- Food Safety- Biosecurity Products' stands at $4.29 million. The estimate points to a change of -63.7% from the year-ago quarter.

Based on the collective assessment of analysts, 'Revenues- Food Safety- Bacterial & General Sanitation' should arrive at $40.39 million. The estimate indicates a change of +1.3% from the prior-year quarter.

The collective assessment of analysts points to an estimated 'Revenues- Animal Safety- Biosecurity Products' of $18.96 million. The estimate indicates a change of -20.4% from the prior-year quarter.

View all Key Company Metrics for Neogen here>>>

Shares of Neogen have demonstrated returns of -12% over the past month compared to the Zacks S&P 500 composite's -4.2% change. With a Zacks Rank #4 (Sell), NEOG is expected to lag the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .

Neogen Corporation (NASDAQ:NEOG) will release earnings for its third quarter before the opening bell on Thursday, April 9.

Analysts expect the Lansing, Michigan-based company to report quarterly earnings of 5 cents per share, down from 10 cents per share in the year-ago period. The consensus estimate for Neogen's quarterly revenue is $204.62 million (it reported $220.98 million last year), according to Benzinga Pro.

On March 2, Neogen announced the sale of Genomics business to Zoetis.

Neogen shares rose 1.6% to close at $9.56 on Monday.

Benzinga readers can access the latest analyst ratings on the Analyst Stock Ratings page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.

Let's have a look at how Benzinga's most-accurate analysts have rated the company in the recent period.

Considering buying NEOG stock? Here’s what analysts think:

Photo via Shutterstock

Market News and Data brought to you by Benzinga APIs

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

To add Benzinga News as your preferred source on Google, click here.

LANSING, Mich.--(BUSINESS WIRE)--Neogen® Corporation (NASDAQ: NEOG), an innovative leader in food safety solutions, announced its financial results for the fiscal third quarter of 2026 and provided updated full fiscal year 2026 financial guidance.

“We continued to make significant progress on our strategic transformation in the third quarter as we look to stabilize and strengthen our core business. We are emboldened by the continued strength in core growth in our Food Safety segment. Combined with our major strategic sales initiatives such as our go-to-market strategy review, our increasing use of metric-based key performance indicators, and our transition to a standardized global solutions based selling approach, we believe we are well positioned for continued fundamental improvement across the organization,” said Mike Nassif, Neogen’s Chief Executive Officer and President.

He continued, “In the third quarter our Animal Safety business suffered several third-party, supply-based, setbacks leading to lower-than-anticipated growth, and we are actively engaged in improving these production-related challenges through our supplier qualification and sales and operations planning process. Despite these transient issues, we were able to deliver strong adjusted EBITDA through solid cost control and we continue to see opportunities to drive efficiency through technology and process across the company. We are confident that we will emerge from this fiscal year stronger and more capable as an organization, and increasingly focused on building upon our market leading position in Food Safety through discipline, improved enterprise capabilities, a renewed focus on innovation leadership, and a dramatically improved selling process.”

Financial Highlights

Revenue by Products and Geography

      Three months ended
February 28,

Nine months ended
February 28,

  2026

2025

Change %

2026

2025

Change % 

Food Safety

  Natural Toxins & Allergens

$

17.9

$

17.6

1.7

%

$

58.3

$

58.5

(0.3

)%

Bacterial & General Sanitation

42.1

39.9

5.5

%

128.7

122.3

5.2

%

Indicator Testing & Culture Media

83.0

74.8

11.0

%

245.9

232.9

5.6

%

Biosecurity Products

3.9

11.8

(66.9

)%

14.3

35.7

(59.9

)%

Genomics Services

6.2

5.7

8.8

%

18.0

17.1

5.3

%

Other

3.6

3.0

20.0

%

9.1

9.8

(7.1

)%

Total Food Safety Revenue

$

156.7

$

152.8

2.6

%

$

474.3

$

476.3

(0.4

)%

Animal Safety

  Life Sciences

$

1.5

$

1.5

—

$

4.8

$

4.9

(2.0

)%

Veterinary Instruments & Disposables

15.5

15.5

—

41.1

45.4

(9.5

)%

Animal Care & Other

5.9

10.4

(43.3

)%

22.3

26.7

(16.5

)%

Biosecurity Products

15.0

23.8

(37.0

)%

52.2

66.6

(21.6

)%

Genomics Services

16.6

17.0

(2.4

)%

50.4

49.3

2.2

%

Total Animal Safety Revenue

$

54.5

$

68.2

(20.1

)%

$

170.8

$

192.9

(11.5

)%

Total Revenues

$

211.2

$

221.0

(4.4

)%

$

645.1

$

669.2

(3.6

)%

  Three months ended
February 28,

Nine months ended
February 28,

2026

2025

Change %

2026

2025

Change %

Domestic

$

102.3

$

115.4

(11.4

)%

$

314.8

$

333.5

(5.6

)%

International

108.9

105.6

3.1

%

330.3

335.7

(1.6

)%

Total revenue

$

211.2

$

221.0

(4.4

)%

$

645.1

$

669.2

(3.6

)%

Revenues for the third quarter were $211.2 million, a decrease of 4.4% when compared to $221.0 million in the prior year. Core revenue, which excludes the impacts of foreign currency translation, as well as divestitures completed and product lines discontinued in the last 12 months, increased by 0.1%. Food Safety segment revenue was $156.7 million in the third quarter, increasing 2.6% relative to the third quarter of fiscal year 2025. Core Food Safety revenue increased 4.0% on a year-over-year basis. The company saw especially strong growth in the quarter from indicators and culture media which was up 11.0% and from bacterial and general sanitation which was up 5.5%. Animal Safety segment revenue was $54.5 million in the third quarter, decreasing 20.1% relative to the third quarter of fiscal year 2025. Core Animal Safety revenue decreased (8.7%) on a year-over-year basis. The company experienced a number of third-party supplier issues in the quarter, which negatively impacted revenue. Domestic revenue in the quarter was $102.3 million and international revenue was $108.9 million. The company saw strong growth in Europe and Latin America, and U.S growth was negatively impacted by the Animal Safety supplier challenges given sales of these products predominately occur in the U.S. Summary of Income Statement

  Three months ended
February 28,

Nine months ended
February 28,

2026

2025

2026

2025

Revenue

$

211.2

$

221.0

$

645.1

$

669.2

Cost of revenues

112.2

110.7

344.4

340.7

Gross profit

99.0

110.3

300.7

328.5

Gross Margin

46.9

%

49.9

%

46.6

%

49.1

%

Operating expenses

102.3

104.9

325.4

778.3

Operating loss (income)

$

(3.3

)

$

5.4

$

(24.7

)

$

(449.8

)

Operating Margin

(1.6

)%

2.4

%

(3.8

)%

(67.2

)%

EBITDA

$

22.5

$

36.7

$

133.7

$

(360.7

)

EBITDA Margin

10.7

%

16.6

%

20.7

%

(53.9

)%

Net (Loss) Income

$

(17.0

)

$

(10.9

)

$

3.4

$

(479.8

)

Net (Loss) Earnings Per Diluted Share

$

(0.08

)

$

(0.05

)

$

0.02

$

(2.21

)

Adjusted Gross Profit

$

109.2

$

113.5

$

325.9

$

344.7

Adjusted Gross Margin

51.7

%

51.4

%

50.5

%

51.5

%

Adjusted Operating Income

$

42.2

$

42.6

$

114.8

$

126.1

Adjusted Operating Margin

20.0

%

19.3

%

17.8

%

18.8

%

Adjusted EBITDA

$

48.2

$

48.6

$

132.4

$

143.6

Adjusted EBITDA Margin

22.8

%

22.0

%

20.5

%

21.5

%

Adjusted Net Income

$

19.4

$

20.9

$

51.5

$

59.6

Adjusted Earnings Per Share

$

0.09

$

0.10

$

0.24

$

0.27

Gross margin was 46.9% in the third quarter of fiscal 2026. This compares to a gross margin of 49.9% in the same quarter a year ago, with the decrease primarily due to duplicative costs related to the company’s Petrifilm manufacturing transition with some impact from tariff costs and inventory write-offs. Excluding integration-related costs, third quarter Adjusted Gross Margin1 was 51.7% compared to 51.4% in the prior-year quarter. Net loss for the third quarter was $17.0 million, or $(0.08) per diluted share, compared to a net loss of $10.9 million, or $(0.05) per diluted share, in the prior-year period. Adjusted Net Income for the third quarter was $19.4 million, or $0.09 per diluted share, compared to $20.9 million, or $0.10 per diluted share, in the prior-year period. Third-quarter Adjusted EBITDA was $48.2 million, representing an Adjusted EBITDA Margin of 22.8%, compared to $48.6 million and a margin of 22.0% in the prior-year period. The higher adjusted EBITDA Margin was the result predominantly of cost saving initiatives implemented at the end of the first quarter of fiscal year 2027 leading to lower operating expense spend. Business and Operational Highlights

Neogen is currently completing a review of its global go-to-market strategy. As part of this review, the company plans to realign resources to higher‑return markets, establish unified solutions‑based selling standards for all global markets, and enhancing performance rigor through metric-based analysis under new commercial leadership Neogen advanced the transition to its new Petrifilm® manufacturing line. The company has completed validation on 100% of Petrifilm equipment and is actively engaged in both operational and performance validation of multiple SKUs. The company remains on track with previous timelines to have its manufacturing transition completed by November 2026. Neogen announced that it has entered into a definitive agreement to sell its global Genomics business to Zoetis Inc. for a purchase price of $160.0 million, subject to customary closing adjustments. The deal is expected to close by the end of the company’s second quarter of fiscal year 2027. Net proceeds from the transaction after closing costs and taxes are anticipated to be approximately $140.0 million. Financial Guidance

  (in millions)

Updated FY26 Guidance

Previous FY26 Guidance

Increase at Midpoint

Revenue

$857 - $860

$845 - $855

$

8.5

Adjusted EBITDA1

Approximately $175

Approximately $175

$

—

The company is increasing its fiscal year 2026 revenue guidance and is now calling for revenue of $857 million to $860 million and is maintaining its adjusted EBITDA guidance of approximately $175 million. This compares with previous revenue guidance which called for revenue of $845 million to $855 million. Adjusted EBITDA is a non-GAAP measure. The Company is not able to reconcile the Adjusted EBITDA outlook to the most directly comparable GAAP measure, forecasted net income, on a forward-looking basis without unreasonable efforts. This is due to the inherent difficulty in forecasting certain items that are necessary for such reconciliation, including (without limitation) non-cash stock-based compensation expense, integration-related expenses, restructuring and transformation-related costs, impairment charges, and the related tax effects of these items. These items are uncertain, depend on various factors outside of the Company’s control, and could be material to the Company’s results calculated in accordance with GAAP. Accordingly, the Company is unable to provide a probable significance of the unavailable information, but such unavailable information could have a potentially significant impact on the Company’s actual net income for fiscal year 2026.

Conference Call and Webcast

Neogen Corporation will host a conference call today at 8:00 a.m. Eastern Time to discuss the Company’s financial results. The live webcast of the conference call and accompanying presentation materials can be accessed through Neogen’s website at neogen.com/investor-relations. For those unable to access the webcast, the conference call can be accessed by dialing 1-800-549-8228 (North America) or (+1) 646-564-2877 (International) and requesting the Neogen Corporation Third Quarter 2026 Earnings Call (conference ID 70064). A replay of the conference call and webcast will be available shortly following the conclusion of the call, and can be accessed domestically or internationally by dialing 1-888-660-6264 or (+1) 646-517-3975, respectively, and providing the entry code 70064#, or through Neogen’s Investor Relations website at neogen.com/investor-relations.

About Neogen

Neogen Corporation is committed to fueling a brighter future for global food security through the advancement of human and animal well-being. Harnessing the power of science and technology, Neogen has developed comprehensive solutions spanning the Food Safety, Livestock, and Pet Health & Wellness markets. A world leader in these fields, Neogen has a presence in over 140 countries with a dedicated network of scientists and technical experts focused on delivering optimized products and technology for its customers.

Safe Harbor Statement

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, among others, statements regarding our outlook, guidance and objectives; plans and expectations relating to our manufacturing transitions (including Petrifilm), supply chain remediation, commercial initiatives and cost-efficiency programs; expected timing and effects of portfolio actions (including the announced divestiture of the genomics business); capital allocation and deleveraging goals; market conditions and demand trends; and any other statements that are not historical facts. In some cases, you can identify forward-looking statements by terms such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “project,” “should,” “target,” “will,” and similar expressions, and their negatives.

These “forward-looking statements” are management’s present expectations of future events as of the date hereof and are subject to a number of known and unknown risks and uncertainties that could cause actual results, conditions, and events to differ materially and adversely from those anticipated.

These risks include, but are not limited to risks relating to the integration of the 3M Food Safety business, risks related to potential tax benefits realized through the 3M transaction, risks related to tariffs and other trade measures, risks related to our international operations and expansion into new geographic markets, risks related to identified material weaknesses in our internal control over financial reporting, risks related to promoting internal growth and identifying and integrating acquisitions, risks related to failure of our systems infrastructure and security breaches of our information systems, risks related to disruption in our manufacturing and service operations, risks related to disruption of third-party package delivery services or pricing increases, risks related to dependence on key suppliers, risks related to the use of distributors for product sales, risks related to the development of new products and technologies, risks related to our ability to maintain a positive reputation, risks related to customer loss, risks related to increased raw material costs, risks related to anti-bribery, trade control, trade sanctions, and anti-corruption laws, risks related to changes in domestic and foreign laws and regulations, risks related to tax audits and changes in tax laws in different jurisdictions, risks related to deterioration in profitability, cash flow, and asset impairments, risks related to competition, risks related to agricultural marketplace, risks related to our substantial indebtedness, risks related to the outcomes of litigation and other legal proceedings, risks related to our ability to obtain and protect intellectual property, risks related to patent infringement challenges, risks related to governmental regulation, risks related to our ability to attract and retain key personnel, risks related to product or service liability claims, risks related to changing political conditions, risks related to climate change, risks related to our inability to meet stakeholder expectations around environmental, social, and governance objectives, risks related to tax legislation, and other factors discussed under the heading “Risk Factors” contained in Item 1A of the company’s Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) on July 30, 2025, as well as any updates to those risk factors filed from time to time in the company’s Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. Neogen is not under any obligation, and it expressly disclaims any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise except as required by law.

Neogen Corporation

Condensed Consolidated Statements of Operations (unaudited)

(in millions, except per share amounts)

  Three months ended
February 28,

Nine months ended
February 28,

2026

2025

2026

2025

Revenues

Product revenues

$

186.2

$

196.5

$

569.4

$

596.6

Service revenues

25.0

24.5

75.7

72.6

Total Revenues

211.2

221.0

645.1

669.2

Cost of Revenues

Cost of product revenues

96.0

95.8

296.6

293.5

Cost of service revenues

16.2

14.9

47.8

47.2

Total Cost of Revenues

112.2

110.7

344.4

340.7

Gross Profit

99.0

110.3

300.7

328.5

Operating Expenses

Sales and marketing

38.2

44.6

125.5

136.9

General and administrative

60.3

55.8

186.4

165.2

Goodwill impairment

—

—

—

461.4

Research and development

3.8

4.5

13.5

14.8

Total Operating Expenses

102.3

104.9

325.4

778.3

Operating Loss (Income)

(3.3

)

5.4

(24.7

)

(449.8

)

Other (Expense) Income

Interest expense, net

(13.9

)

(17.0

)

(43.7

)

(52.0

)

Gain on sale of business

—

—

76.4

—

Other, net

(3.1

)

1.9

(4.9

)

(0.1

)

Total Other (Expense) Income

(17.0

)

(15.1

)

27.8

(52.1

)

(Loss) Income Before Taxes

(20.3

)

(9.7

)

3.1

(501.9

)

Income Tax (Benefit) Expense

(3.3

)

1.2

(0.3

)

(22.1

)

Net (Loss) Income

$

(17.0

)

$

(10.9

)

$

3.4

$

(479.8

)

Net (Loss) Income Per Share

Basic

$

(0.08

)

$

(0.05

)

$

0.02

$

(2.21

)

Diluted

$

(0.08

)

$

(0.05

)

$

0.02

$

(2.21

)

Weighted Average Shares Outstanding

Basic

217.7

217.0

217.4

216.8

Diluted

217.7

217.0

217.9

216.8

Neogen Corporation

Condensed Consolidated Balance Sheets (unaudited)

  (in millions, except per share amounts)

February 28, 2026

May 31, 2025

Assets

Current Assets

Cash and cash equivalents

$

159.9

$

129.0

Accounts receivable, net of allowance of $4.1 and $5.4

137.1

153.4

Inventories, net of reserves of $16.5 and $16.5

161.7

190.8

Prepaid expenses and other current assets

63.1

53.3

Assets held for sale

68.2

50.4

Total Current Assets

590.0

576.9

Net Property and Equipment

331.9

339.1

Other Assets

Right of use assets

15.7

17.2

Goodwill

1,047.8

1,064.9

Amortizable intangible assets, net

1,341.8

1,410.5

Other non-current assets

31.8

35.2

Total Assets

$

3,359.0

$

3,443.8

Liabilities and Stockholders’ Equity

Current Liabilities

Current portion of debt

$

—

$

19.3

Accounts payable

75.2

79.6

Accrued compensation

23.5

14.1

Income tax payable

9.9

5.6

Accrued interest

3.5

11.1

Deferred revenue

3.9

5.6

Other current liabilities

28.2

32.1

Liabilities held for sale

6.4

6.6

Total Current Liabilities

150.6

174.0

Deferred Income Tax Liability

269.2

280.9

Non-current debt

793.3

874.8

Other non-current liabilities

43.5

42.9

Total Liabilities

1,256.6

1,372.6

Commitments and Contingencies

Equity

Preferred stock, $1.00 par value, 100,000 shares authorized, none issued and outstanding

—

—

Common stock, $0.16 par value, 315.0 shares authorized, 217.7 and 217.0 shares issued and outstanding

34.8

34.7

Additional paid-in capital

2,613.1

2,601.8

Accumulated other comprehensive loss

(12.5

)

(28.9

)

Accumulated deficit

(533.0

)

(536.4

)

Total Stockholders’ Equity

2,102.4

2,071.2

Total Liabilities and Stockholders’ Equity

$

3,359.0

$

3,443.8

Neogen Corporation

Condensed Consolidated Statements of Cash Flows (unaudited)

(in millions)

  Nine months ended February 28,

2026

2025

Cash Flows provided by Operating Activities

Net income (loss)

$

3.4

$

(479.8

)

Adjustments to reconcile net income (loss) to net cash from operating activities:

Depreciation and amortization

86.9

89.2

Deferred income taxes

(15.5

)

(33.1

)

Share-based compensation

10.4

13.0

Loss on disposal of property and equipment

1.2

0.1

Amortization of debt issuance costs

1.5

2.6

Goodwill and Other asset impairment

—

470.8

Loss on refinancing and extinguishment of debt

0.4

—

Gain on sale of business

(76.4

)

—

Other

(0.2

)

(0.3

)

Change in operating assets and liabilities:

Accounts receivable, net

16.6

9.1

Inventories, net

21.5

(25.1

)

Prepaid expenses and other current assets

(10.0

)

(6.4

)

Accounts payable and accrued liabilities

20.5

6.0

Interest expense accrual

(7.6

)

(7.5

)

Change in other non-current assets and non-current liabilities

0.3

3.2

Net Cash provided by Operating Activities

53.0

41.8

Cash Flows provided by (used for) Investing Activities

Purchases of property, equipment and intangible assets

(47.3

)

(88.5

)

Proceeds from the maturities of marketable securities

—

0.3

Proceeds from sale of business, net of cash divested

121.7

—

Proceeds from the sale of property and equipment and other

0.1

4.9

Net Cash provided by (used for) Investing Activities

74.5

(83.3

)

Cash Flows (used for) provided by Financing Activities

Issuance of shares related to equity compensation and employee stock purchase plan

1.7

2.2

Tax payments related to share-based awards

(0.7

)

(1.5

)

Repayment of finance lease

(0.1

)

(0.2

)

Repayment of outstanding debt

(100.0

)

—

Net Cash (used for) provided by Financing Activities

(99.1

)

0.5

Effects of Foreign Exchange Rate on Cash

2.5

(1.9

)

Net Increase (Decrease) in Cash and Cash Equivalents

30.9

(42.9

)

Cash and Cash Equivalents, Beginning of Year

129.0

170.6

Cash and Cash Equivalents, End of Year

$

159.9

$

127.7

Supplemental cash flow information

Property and equipment obtained for noncash consideration

$

—

$

0.9

Right of use assets obtained in exchange for new operating lease liabilities

$

4.4

$

7.0

Statement regarding use of non-GAAP financial measures

This press release includes certain non-GAAP financial measures, which management believes are useful to investors, securities analysts and other interested parties. Management uses Adjusted EBITDA as a key profitability measure. This is a non-GAAP measure that represents EBITDA before certain items that impact comparison of the performance of our business, either period-over-period or with other businesses. Adjusted EBITDA Margin is Adjusted EBITDA for a particular period expressed as a percentage of revenues for that period.

Management uses Adjusted Gross Profit as an additional measure of profitability. Adjusted Gross Profit is a non-GAAP measure that represents net income before certain items that impact comparison of the performance of our business, either period-over-period or with other businesses.

Management uses Adjusted Operating Income as an additional measure of profitability. Adjusted Operating Income is a non-GAAP measure that represents operating income before certain items that impact comparison of the performance of our business, either period-over-period or with other businesses.

Management uses Adjusted Net Income as an additional measure of profitability. Adjusted Net Income is a non-GAAP measure that represents net income before certain items that impact comparison of the performance of our business, either period-over-period or with other businesses.

Core revenue growth is a non-GAAP measure that represents net sales for the period excluding the effects of foreign currency translation rates and the impacts of acquisitions and discontinued product lines, where applicable. Core revenue growth is presented to allow for a meaningful comparison of year-over-year performance without the volatility caused by foreign currency translation rates, or the incomparability that would be caused by the impact of an acquisition, disposal or product line discontinuation.

These non-GAAP financial measures should be considered only as supplemental to, and not as superior to, financial measures prepared in accordance with GAAP. Please see below for a reconciliation of historical non-GAAP financial measures to the most directly comparable financial measures prepared in accordance with GAAP.

NEOGEN CORPORATION

RECONCILIATION OF NET (LOSS) INCOME TO ADJUSTED EBITDA (UNAUDITED)

(in millions)

  Three months ended
February 28,

Nine months ended
February 28,

2026

2025

2026

2025

Net (Loss) Income

$

(17.0

)

$

(10.9

)

$

3.4

$

(479.8

)

Income tax (benefit) expense

$

(3.3

)

$

1.2

$

(0.3

)

(22.1

)

Depreciation and amortization

28.9

29.4

86.9

89.2

Interest expense, net

13.9

17.0

43.7

52.0

EBITDA

$

22.5

$

36.7

$

133.7

$

(360.7

)

Share-based compensation

1.1

4.2

10.4

13.0

FX transaction loss (gain) on loan and other revaluation (1)

1.9

(0.3

)

2.1

(0.2

)

Transaction costs (2)

3.7

0.5

8.9

1.6

3M integration costs (3)

0.4

0.6

1.1

5.4

Sample collection transition and ramp up costs (4)

4.6

2.9

13.4

4.7

Petrifilm duplicate manufacturing costs (5)

4.1

0.7

9.8

0.8

Transformation initiatives and related costs (6)

5.3

2.5

16.2

3.3

Restructuring (7)

0.4

0.2

6.9

10.1

Goodwill impairment

—

—

—

461.4

Contingent consideration adjustments

0.9

0.5

0.9

0.5

ERP expense (8)

0.6

0.6

1.7

3.2

Gain on sale of business

—

—

(76.4

)

—

Other

2.7

(0.5

)

3.7

0.5

Adjusted EBITDA

$

48.2

$

48.6

$

132.4

$

143.6

Adjusted EBITDA margin (% of sales)

22.8

%

22.0

%

20.5

%

21.5

%

(1) Net foreign currency transaction loss (gain) associated with the revaluation of foreign-currency-denominated intercompany loans.

(2) Includes legal, accounting, tax, consulting and other related costs to execute corporate transactions and capital structure initiatives.

(3) Includes costs associated with 3M transition agreements and related integration costs.

(4) Includes costs associated with transitioning off the 3M transition contract manufacturing agreement and ramp-up costs associated with our sample collection product line.

(5) Duplicate costs associated with the startup of Petrifilm manufacturing.

(6) Includes consulting and other costs, including severance, associated with transformation initiatives.

(7) Severance, non-cash impairment, and other related exit costs primarily associated with a reduction in our global headcount and global genomics business.

(8) Expenses related to ERP implementation.

NEOGEN CORPORATION

RECONCILIATION OF NET (LOSS) INCOME TO ADJUSTED NET INCOME (UNAUDITED)

(in millions)

  Three months ended
February 28,

Nine months ended
February 28,

2026

2025

2026

2025

Net (Loss) Income

$

(17.0

)

$

(10.9

)

$

3.4

$

(479.8

)

Amortization of acquisition-related intangibles

22.0

22.9

66.9

69.2

Share-based compensation

1.1

4.2

10.4

13.0

FX transaction loss (gain) on loan and other revaluation (1)

1.9

(0.3

)

2.1

(0.2

)

Transaction costs (2)

3.7

0.5

8.9

1.6

3M integration costs (3)

0.4

0.6

1.1

5.4

Sample collection transition and ramp up costs (4)

4.6

2.9

13.4

4.7

Petrifilm duplicate manufacturing costs (5)

4.1

0.7

9.8

0.8

Transformation initiatives and related costs (6)

5.3

2.5

16.2

3.3

Restructuring (7)

0.4

0.2

6.9

10.1

Goodwill impairment

—

—

-

461.4

Contingent consideration adjustments

0.9

0.5

0.9

0.5

ERP expense (8)

0.6

0.6

1.7

3.2

Gain on sale of business

—

—

(76.4

)

—

Other

2.7

(0.5

)

3.7

0.5

Estimated tax effect of above adjustments (9)

(11.3

)

(3.0

)

(17.5

)

(34.1

)

Adjusted Net Income

19.4

$

20.9

$

51.5

59.6

Adjusted Earnings Per Share

$

0.09

$

0.10

$

0.24

$

0.27

(1) Net foreign currency transaction loss (gain) associated with the revaluation of foreign-currency-denominated intercompany loans.

(2) Includes legal, accounting, tax, consulting and other related costs to execute corporate transactions and capital structure initiatives.

(3) Includes costs associated with 3M transition agreements and related integration costs.

(4) Includes costs associated with transitioning off the 3M transition contract manufacturing agreement and ramp-up costs associated with our sample collection product line.

(5) Duplicate costs associated with the startup of Petrifilm manufacturing.

(6) Includes consulting and other costs, including severance, associated with transformation initiatives.

(7) Severance, non-cash impairment, and other related exit costs primarily associated with a reduction in our global headcount and global genomics business.

(8) Expenses related to ERP implementation.

(9) Tax effect of adjustments is calculated using projected effective tax rates for each applicable item.

NEOGEN CORPORATION

RECONCILIATION OF GROSS PROFIT TO ADJUSTED GROSS PROFIT (UNAUDITED)

(in millions)

  Three months ended February 28,

Nine months ended February 28,

2026

2025

2026

2025

Gross Profit

$

99.0

$

110.3

$

300.7

$

328.5

Transaction costs (1)

0.5

—

0.5

—

3M integration costs (2)

0.4

0.6

1.1

5.4

Sample collection transition and ramp up costs (3)

4.6

2.9

13.4

4.7

Petrifilm duplicate manufacturing costs (4)

4.1

0.7

9.8

0.8

Restructuring (5)

—

(0.3

)

—

4.6

Other

0.6

(0.7

)

0.4

0.7

Adjusted Gross Profit

$

109.2

$

113.5

$

325.9

$

344.7

(1) Includes certain manufacturing costs to execute corporate transactions.

(2) Includes costs associated with 3M transition agreements and related integration costs.

(3) Includes costs associated with transitioning off the 3M transition contract manufacturing agreement and ramp-up costs associated with our sample collection product line.

(4) Duplicate costs associated with the startup of Petrifilm manufacturing.

(5) Non-cash impairment and other related exit costs primarily associated with a reduction in our global genomics business.

NEOGEN CORPORATION

RECONCILIATION OF OPERATING (LOSS) INCOME TO ADJUSTED OPERATING INCOME (UNAUDITED)

(in millions)

  Three months ended
February 28,

Nine months ended
February 28,

2026

2025

2026

2025

Operating (Loss) Income

$

(3.3

)

$

5.4

$

(24.7

)

$

(449.8

)

Amortization of acquisition-related intangibles

22.0

22.9

66.9

69.2

Share-based compensation

1.1

4.2

10.4

13.0

Transaction costs (1)

3.7

0.5

8.3

1.6

3M Integration costs (2)

0.4

0.6

1.1

5.4

Sample collection transition and ramp up costs (3)

4.6

2.9

13.4

4.7

Petrifilm duplicate manufacturing costs (4)

4.1

0.7

9.8

0.8

Transformation initiatives and related costs (5)

5.3

2.5

16.2

3.3

Restructuring (6)

0.4

0.2

6.9

10.1

Goodwill impairment

—

—

—

461.4

ERP expense (7)

0.6

0.6

1.7

3.2

Other

3.3

2.1

4.8

3.2

Adjusted Operating Income

$

42.2

$

42.6

$

114.8

$

126.1

(1) Includes legal, accounting, tax, consulting and other related costs to execute corporate transactions and capital structure initiatives.

(2) Includes costs associated with 3M transition agreements and related integration costs.

(3) Includes costs associated with transitioning off the 3M transition contract manufacturing agreement and ramp-up costs associated with our sample collection product line.

(4) Duplicate costs associated with the startup of Petrifilm manufacturing.

(5) Includes consulting and other costs, including severance, associated with transformation initiatives.

(6) Severance, non-cash impairment, and other related exit costs primarily associated with a reduction in our global headcount and global genomics business.

(7) Expenses related to ERP implementation.

NEOGEN CORPORATION

RECONCILIATION OF GROWTH TO CORE GROWTH

(In millions)

  Q3 FY26

Q3 FY25

Growth

Foreign Currency

Acquisitions
/Divestitures

Core
Revenue
Growth

Food Safety

$

156.7

$ 152.8

2.6

%

4.0

% (5.4

%)

4.0

% Animal Safety

$

54.5

$ 68.2

(20.1

%)

0.5

% (11.9

%)

(8.7

%) Total Neogen

$

211.2

$ 221.0

(4.4

%)

3.0

% (7.5

%)

0.1

%  

Neogen (NEOG - Free Report) came out with quarterly earnings of $0.09 per share, beating the Zacks Consensus Estimate of $0.04 per share. This compares to earnings of $0.1 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of +125.00%. A quarter ago, it was expected that this maker of medical testing kits would post earnings of $0.07 per share when it actually produced earnings of $0.1, delivering a surprise of +42.86%.

Over the last four quarters, the company has surpassed consensus EPS estimates two times.

Neogen, which belongs to the Zacks Medical - Products industry, posted revenues of $211.2 million for the quarter ended February 2026, surpassing the Zacks Consensus Estimate by 3.30%. This compares to year-ago revenues of $220.98 million. The company has topped consensus revenue estimates four times over the last four quarters.

The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.

Neogen shares have added about 47.9% since the beginning of the year versus the S&P 500's decline of 0.9%.

What's Next for Neogen?While Neogen has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Ahead of this earnings release, the estimate revisions trend for Neogen was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $0.07 on $211.7 million in revenues for the coming quarter and $0.28 on $850.08 million in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Products is currently in the bottom 38% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

Another stock from the same industry, Envista (NVST - Free Report) , has yet to report results for the quarter ended March 2026.

This maker of dental products is expected to post quarterly earnings of $0.31 per share in its upcoming report, which represents a year-over-year change of +29.2%. The consensus EPS estimate for the quarter has been revised 0.5% lower over the last 30 days to the current level.

Envista's revenues are expected to be $673.52 million, up 9.2% from the year-ago quarter.

Neogen Corporation (NEOG) Q3 2026 Earnings Call Transcript

Key Takeaways NEOG reported Q3 adjusted EPS of 9 cents and revenues of $211.2M, both topping estimates.NEOG's core revenues were up slightly, but divestitures and Animal Safety weakness dragged down sales.Neogen sees gross margin contraction and operating loss despite higher revenue guidance. Neogen Corporation (NEOG - Free Report) reported third-quarter fiscal 2026 adjusted earnings per share (EPS) of 9 cents, down 10% year over year.  However, the metric topped the Zacks Consensus Estimate by 125%.

Neogen’s Q3 RevenuesRevenues in the quarter decreased 4.4% on a year-over-year basis to $211.2 million. Meanwhile, core revenues increased 0.1%. Divestitures and discontinued product lines had a negative impact of 7.5%, while foreign currency had a positive impact of 3%. The metric topped the Zacks Consensus Estimate by 3.3%.

Following the announcement yesterday, NEOG stock fell 2.95% to close the session at $10.04.   

Neogen’s Segments in DetailThe company's Food Safety segment registered revenues of $156.7 million in the fiscal third quarter, up 2.6% year over year. This consisted of 4% core revenue growth, a negative 5.4% impact of divestitures and discontinued product lines and a positive foreign currency impact of 4%. Our model projected Food Safety revenues to be $146.6 million for the fiscal third quarter.

Revenues from the Animal Safety segment totaled $54.5 million, down 20.1% year over year. This consisted of an 8.7% core revenue decrease, a favorable 0.5% foreign currency impact and a negative 11.9% impact of divestitures and discontinued product lines. Our model’s projection for the business was $57.1 million.

Neogen’s Margin DetailsIn the third quarter of fiscal 2026, gross profit declined 10.2% year over year to $99 million. The cost of revenues edged up 1.4% to $112.2 million. The gross margin contracted 303 basis points (bps) year over year to 46.9%.

Sales and marketing expenses amounted to $38.2 million, down 14.4% year over year, whereas administrative expenses increased 8.1% from the prior-year quarter’s level to $60 million. R&D expenses totaled $3.8 million, down 15.6% year over year. The quarter recorded an operating loss of $3.3 million compared to an operating profit of $5.4 million in the year-ago period.  

Neogen’s Q3 Cash PositionNeogen’s cash and cash equivalents at the end of the fiscal third quarter totaled $137.1 million compared with $145.3 million at the end of the second quarter.

Cumulative net cash provided by operating activities came in at $53 million compared with $41.8 million a year ago.

Neogen’s Fiscal 2026 OutlookThe company raised its fiscal 2026 revenue projection, now expecting between $857 million and $860 million (previously $845 million-$855 million). The Zacks Consensus Estimate for the same currently stands at $850.1 million.

Adjusted EBITDA is expected to be roughly $175 million (same as earlier).

Our Take on NEOGNeogen ended the fiscal third quarter with better-than-expected earnings and revenues. However, both metrics were down on a year-over-year basis. The Animal Safety business experienced several third-party, supply-based setbacks, resulting in lower-than-anticipated growth. The contraction of gross margin in the quarter is also discouraging.

On a promising note, the Food Safety segment delivered another quarter of core revenue growth and was consistent with current market dynamics. Neogen made significant progress on its strategic initiatives, such as commercial prowess, high-impact innovation and operational efficiency, to stabilize and strengthen its core business. The raised revenue guidance for the year appears promising.

The company recently announced that it has entered into a definitive agreement to sell its global Genomics business to Zoetis Inc. for a purchase price of $160.0 million, subject to customary closing adjustments. The deal is expected to close by the end of the second quarter of fiscal year 2027. 

NEOG’s Zacks Rank and Key PicksNeogen currently carries a Zacks Rank #3 (Hold).

Some better-ranked stocks from the broader medical space are Globus Medical (GMED - Free Report) , Phibro Animal Health (PAHC - Free Report) and IDEXX Laboratories (IDXX - Free Report) .

Globus Medical, currently sporting a Zacks Rank #1 (Strong Buy), reported fourth-quarter 2025 adjusted EPS of $1.28, topping the Zacks Consensus Estimate by 20.76%. Revenues of $826.4 million beat the Zacks Consensus Estimate by 4.9%. You can see the complete list of today’s Zacks #1 Rank stocks here.

GMED’s earnings yield of 4.8% favorably compares with the industry’s negative 1.6% yield. The company surpassed earnings estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 18.8%.

Phibro Animal Health, carrying a Zacks Rank #2 (Buy) at present, posted second-quarter fiscal 2026 adjusted EPS of 87 cents, exceeding the Zacks Consensus Estimate by 27.01%. Revenues of $373.9 million surpassed the Zacks Consensus Estimate by 4.72%.

PAHC has an estimated long-term earnings growth rate of 21.5% compared with the industry’s 12% growth. The company’s earnings outpaced estimates in each of the trailing four quarters, with the average surprise being 20.15%.

IDEXX Laboratories, carrying a Zacks Rank #2, reported a fourth-quarter 2025 EPS of $3.08, which surpassed the Zacks Consensus Estimate by 18%. Revenues of $1.09 billion topped the Zacks Consensus Estimate by 1.86%.

IDXX has an earnings yield of 2.5% compared with the industry’s negative 1.6% yield. The company’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 6.11%.

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

© Leon Neal / Getty Images

Match Group (NASDAQ:MTCH | MTCH Price Prediction) stock got a double dose of positive analyst attention on May 6. The company saw TD Cowen raise its MTCH stock price target to $46 from $44 while keeping a Buy rating, citing “several positive user signals” at Tinder during the quarter. UBS analyst Stephen Ju lifted his target to $38 from $34, keeping a Neutral rating following better-than-expected Q1 2026 results and Q2 guidance.

The split between TD Cowen’s bullish $46 Buy and UBS’s cautious $38 Neutral captures the central debate around Match Group stock: is the long-awaited Tinder turnaround real, or stabilization that may not translate into renewed growth? For prudent investors, the answer matters because Tinder remains the company’s largest revenue contributor. For broader context on dating app sector dynamics, see our recent Match Group coverage.

Ticker Company Firm Action Old Rating New Rating Old Target New Target MTCH Match Group TD Cowen Price target raised Buy Buy $44 $46 MTCH Match Group UBS Price target raised Neutral Neutral $34 $38 The Analyst’s Case TD Cowen’s Match Group stock price target raised to $46 reflects optimism that Tinder’s product overhaul is showing up in user behavior. The firm flagged “several positive user signals” from the quarter as evidence the multi-year turnaround now has supporting data.

UBS framed its view as “constructive but still cautious.” Stephen Ju cited Match Group’s slower MAU declines, improving retention, and modest payer trend improvement, while flagging ongoing investment spending and mixed regional pressure. The Neutral rating suggests that UBS wants more proof before underwriting re-acceleration.

Company Snapshot Match Group operates Tinder, Hinge, Match, Plenty of Fish, OkCupid, Meetic, and several smaller brands. Tinder Q1 2026 direct revenue came in at $455 million, with payers down 5% to 8.6 million, a meaningful improvement from the 8% decline in Q4 2025.

Hinge remains the bright spot, with Q1 direct revenue of $194 million (+28%) and payers up 15% to 2.0 million. CEO Spencer Rascoff reiterated Hinge’s “Path to $1 billion business by 2027.”

Why the Move Matters Now MTCH stock trades at around $38.50, near the top of its 52-week range of $26.18 to $38.94. The shares are up 19% year to date and 20% over the past month, helped by Tinder’s March MAU decline of 7%, the slowest rate in 31 months.

At a forward P/E ratio of 10x and trailing P/E ratio of 16x, Match Group stock isn’t priced for heroic re-acceleration. The company also raised its quarterly dividend by 5% to $0.20, with $959 million remaining on its buyback authorization.

What It Means for Your Portfolio The bull case rests on a simple sequence: stabilization first, re-acceleration later. Match Group has poured product investment and AI-driven recommendation work into Tinder, and Q1 metrics suggest the worst of the user erosion may be behind it.

The bear case is equally defensible. Hinge’s outperformance has masked Tinder weakness for years, and if Hinge growth eventually decelerates while Tinder only stabilizes, the consolidated growth profile stays muted. Tinder’s March monthly active user (MAU) decline of FY2026 revenue guidance of $3.41 billion to $3.54 billion (roughly flat at the midpoint) underscores that risk.

For prudent Match Group investors, the gap between TD Cowen’s $46 Buy and UBS’s $38 Neutral is the story. Stabilization appears real, yet conviction on durable growth requires more quarters of data. Modest position sizing while the turnaround thesis matures looks reasonable.

"Gen Z is the loneliest generation. They desperately want to connect.

Match topped revenue estimates as Tinder user declines moderated and Hinge delivered 28% direct revenue growth. Summary

Tinder’s reset is gaining traction, but second-quarter revenue may still decline.

Match Group MTCH gave investors a first-quarter report that looked stronger than Wall Street expected, as revenue rose 4% from a year earlier to $864 million, ahead of the $855 million estimate. The result suggests the company's turnaround strategy may be starting to show signs of traction, particularly as Tinder's user declines moderated and newer product features appeared to resonate with younger daters. Match cited growing momentum from Tinder's ongoing product enhancements, while shares rose less than 1% in extended trading after the report. The stock has gained 18% this year, compared with a 5% increase in the S&P 500, giving investors another reason to watch whether the company's product reset can possibly translate into more durable user and revenue growth.

The sharper focus is still on Tinder, where monthly active users fell 7% in March, improving from a 10% decline a year earlier and marking the slowest drop in two and a half years. New user registrations grew for the first time since 2024, though only by 1%, while the company also said retention among Gen Z women in the US increased. Tinder generated first-quarter revenue of $454.7, up 2% year-over-year, and Wall Street estimates the app will produce roughly $1.8 billion in revenue this fiscal year. The company pointed to newer features such as Astrology Mode, which lets users add birth details to their profile and view deeper compatibility insights with potential matches, along with face verification designed to reduce interactions with bad actors. CEO Spencer Rascoff said the results are being driven by a combination of resonating features and marketing working alongside them, adding that Tinder is trying to shift how people have viewed the brand for a decade toward what he described as a fun way to safely meet new people.

Still, the second-quarter outlook leaves investors with a more measured setup. Match expects total second-quarter revenue of $850 million to $860 million, which would mark a decline of as much as 2% from a year earlier, compared with Wall Street's roughly $857 million estimate. Adjusted earnings before interest, taxes, depreciation and amortization are expected to come in between $325 million and $330 million for the quarter. Rascoff took the top job early last year after three activist investors amassed stakes and pushed for change, and he has since led an internal reorganization and management shake-up aimed at accelerating product development. Beyond Tinder, Match also owns Hinge, OkCupid and Match.com, with Hinge delivering 28% year-over-year direct revenue growth, largely driven by international expansion and new AI-powered features. Hinge also rolled out face verification, and the company said the app remains on track to become a $1 billion business by 2027.

, /PRNewswire/ -- Match Group (NASDAQ: MTCH) announced today that Steven Bailey, Chief Financial Officer of Match Group, will participate in a fireside chat at the TD Cowen Technology, Media & Telecom Conference on Wednesday, May 27 at 9:05 a.m. Eastern Time (ET). The discussion is expected to cover Match Group's business, strategy, and financial details. A live webcast and replay of the fireside chat will be available at https://ir.mtch.com/news-and-events/events.

About Match Group

Match Group (PRNewsfoto/Match Group) Match Group (NASDAQ: MTCH), through its portfolio companies, is a leading provider of digital technologies designed to help people make meaningful connections. Our global portfolio of brands includes Tinder®, Hinge®, Match®, Meetic®, OkCupid®, Pairs™, PlentyOfFish®, Azar®, BLK®, and more, each built to increase our users' likelihood of connecting with others. Through our trusted brands, we provide tailored services to meet the varying preferences of our users. Our services are available in over 40 languages to our users all over the world.

SOURCE Match Group

Also from this source

Match Group, Inc. (MTCH) Presents at J.P. Morgan 54th Annual Global Technology, Media and Communications Conference Transcript

Tinder is rolling out live events, AI tools and group dating features to reengage younger users amid dating app fatigue. Summary

Tinder’s turnaround strategy now centers on AI, live events and social group connections.

Match Group MTCH is trying to turn Tinder's user fatigue problem into a fresh growth story, as the company pushes live events, AI-powered features and a broader product redesign to bring younger daters back into the app. At a recent Tinder pickleball event near Santa Monica State Beach, the line stretched out the door and the venue hit capacity, giving investors a direct look at how the company is testing real-world meetups as an alternative to endless swiping. Tinder's audience is more than 50% under 30, but the app has been losing users as Gen Z daters change how they approach online dating.

Spencer Rascoff, who took over Match Group early last year and later became Tinder CEO, is putting Tinder at the center of the turnaround because of its scale and revenue importance. Tinder is the No. 1 dating app in more than 185 countries and accounted for more than half of Match's total revenue last year. The company is now rolling out or testing a wider product reset, including live events, face verification, astrology and music modes, Double Date, virtual speed dating, AI-driven Chemistry features, a cleaner redesign and a planned Groups concept that could let users meet through larger friend-based gatherings. Rascoff also said about 80% of Tinder's code is currently written with AI tools, showing how deeply the company is using AI internally as it tries to accelerate product development.

The early numbers suggest the strategy could be gaining traction, though the turnaround is still in progress. Match recently reported a 4% increase in first-quarter revenue, above Wall Street estimates, with Rascoff saying Tinder is “working much better now” after product enhancements. For investors, the key question is whether Tinder can shift from a tired swipe-first brand into a broader connection platform without losing the simplicity that made the product work in the first place. If live events, AI matching and group-based dating improve user outcomes, Tinder could possibly rebuild momentum with younger daters while giving Match a stronger growth narrative after a difficult stretch.

Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact , /PRNewswire/ -- Match Group (NASDAQ: MTCH) today announced the launch of its new quarterly CEO Connection Series, hosted by CEO Spencer Rascoff, beginning with Decoding Gen Z Dating. The event will feature perspectives from Match Group's Consumer Research and Brand Strategy teams on how Gen Z is reshaping connection and dating culture, as well as how Match Group is evolving alongside those shifts.

Match Group (PRNewsfoto/Match Group) The event will be held on Thursday, June 11th at 10:00 a.m. Pacific Time (PT). A live webcast will be available at https://ir.mtch.com/investor-relations/news-events/events-archive and streamed on Spencer Rascoff's LinkedIn and Instagram pages.

About Match Group

Match Group (NASDAQ: MTCH), through its portfolio companies, is a leading provider of digital technologies designed to help people make meaningful connections. Our global portfolio of brands includes Tinder®, Hinge®, Match®, Meetic®, OkCupid®, Pairs™, PlentyOfFish®, Azar®, BLK®, and more, each built to increase our users' likelihood of connecting with others. Through our trusted brands, we provide tailored services to meet the varying preferences of our users. Our services are available in over 40 languages to our users all over the world.

SOURCE Match Group

Also from this source

3 Big Earnings Misses: Is It Time to Buy the Dip?Match Group NASDAQ: MTCH Chief Financial Officer Steven Bailey said Tinder is showing signs that recent product and marketing changes are beginning to translate into stronger user trends and better financial metrics.

Speaking at an investor conference, Bailey said the company’s thesis for improving Tinder is “starting to be proven out,” with early product engagement indicators moving first, followed by broader user and financial metrics.

Get Match Group alerts:

3 Stocks Ringing in The New Year With Large Buyback AnnouncementsBailey pointed to improvements in “Sparks” and “Sparks Coverage,” which he described as measures of meaningful connections, as well as better monthly active user trends and retention. He said Tinder’s MAUs improved from down 10% to down 7%, while retention has also improved.

“That’ll lead to better financial results,” Bailey said. “We’re already starting to see that in payers and revenue, too, where at Tinder, revenue’s coming better than expected lately.”

Tinder Sees Broad-Based Registration Improvement Bumble's Valuation Hits an All-Time Low, Can Its Fortunes Change?Bailey said Tinder recently recorded 1% year-over-year growth in registrations, which he described as the first such increase in “many, many years.” He said the gains were broad-based across many user groups, including men and women, older and younger users, and both U.S. and international markets.

Bailey attributed the improvement to three main factors: a shift in marketing toward more lower-funnel spending, an overall increase in marketing investment, and the traction of new features such as Double Date.

“Features like Double Date, that’s really resonated with Gen Z, is helping that word of mouth flywheel that’s so important to the overall equation, too,” Bailey said.

He said one in four Gen Z women in the U.S. are using Double Date, a feature that lets users pair with a friend and match with other pairs. Bailey said the feature is appealing because it is “fun,” “lightweight,” “lower pressure” and perceived as safer.

In-Person Events Seen as Brand and Engagement Tool Bailey said Match Group is also placing more emphasis on in-real-life, or IRL, connections at Tinder, particularly for Gen Z users. He said the company has piloted about 20 events in Los Angeles and expects to complete 30 soon.

Bailey said the company does not currently view events as a major revenue driver. Instead, he said they are intended to change perceptions of Tinder from a “hookup app” or a source of “swipe fatigue” into an app for meeting new people and forming meaningful real-life connections.

According to Bailey, attendance at the Los Angeles events has been about 85%, and feedback from attendees has been “incredibly strong.” He said about 50% of Gen Z users in Los Angeles surveyed by Tinder expressed interest in attending an event.

Bailey said Tinder is not aiming to become an events company. Instead, it plans to partner with existing events businesses and serve as the technology platform that helps make connections happen.

Algorithm and AI Work Drive Engagement Bailey said changes to Tinder’s recommendation algorithms have been the “biggest win of the year” and are responsible for about two-thirds of the improvement in engagement and retention metrics.

He said the company has shifted algorithmic weighting away from generating as many likes as possible and toward user outcomes and meaningful connections. Bailey said the changes have improved retention while producing less of a revenue hit than the company had anticipated.

Bailey said Tinder currently has six algorithm tests live and continues to look for ways to feed more data into its systems while keeping the user experience light. He cited tests involving AI-enabled camera roll features, which could help users select better photos, improve profiles and provide additional insights to recommendation algorithms with user permission.

“AI is better at inferring what you like, what you dislike,” Bailey said, adding that AI can help gather user data in a less burdensome way than lengthy profile questionnaires.

Hinge Growth Remains Strong Bailey also discussed Hinge, which he said delivered 28% revenue growth in the first quarter and remains on track toward Match Group’s expectation of $1 billion in revenue in 2027, with expanding margins.

He said Hinge still has a long runway for monetization in core markets and is seeing strong growth in Europe. Bailey said revenue in European expansion markets has grown 100% year-over-year for the past three quarters.

Bailey said Hinge has also shown promising early performance in Latin America, including becoming the No. 2 or No. 3 dating app in Mexico and entering Brazil. He said those results give Match Group confidence that Hinge can become a global brand, with Asia representing a largely untapped opportunity.

“We’re, to be honest, talking more and more now about, okay, we’re going to get to the billion through basically momentum,” Bailey said. “How do we get to the $2 billion?”

Bailey said Match Group is keeping Tinder and Hinge distinct, with Tinder positioned around “fun” and Hinge around “focus.” He said users commonly use multiple dating apps, creating opportunities for cross-sell and bundling across Match Group’s portfolio.

Margins, Sniffies Investment and Buybacks Bailey said Match Group’s 2025 margin outlook includes several one-time costs. Excluding those costs, he said margins are roughly flat year-over-year at about 37.5%, by design.

He said the company has generated about $100 million in headcount-related savings and roughly $125 million in in-app payment fee-related savings, and has reinvested much of that into Tinder and Hinge product and marketing.

Bailey also discussed Match Group’s $100 million investment in Sniffies, describing it as a large minority stake that is off-balance sheet and not consolidated. He said Sniffies has about 3 million monthly active users and is the No. 2 player in the non-heterosexual male category. Bailey said Match Group plans to support Sniffies in areas such as trust and safety and in working toward returning to the App Store with a safe-for-work product. He also said Match Group is shutting down Archer, which did not find the product-market fit the company wanted.

On capital allocation, Bailey said Match Group remains a strong free cash flow generator, producing about $1.1 billion in free cash flow in recent years. He said the company expects to reduce its share count by 5% to 7% annually over the next few years through buybacks.

Bailey said free cash flow per share grew more than 20% year-over-year last year and is expected to grow in the high teens this year, calling capital allocation an “underappreciated part” of the company’s turnaround story.

About Match Group NASDAQ: MTCHMatch Group, Inc NASDAQ: MTCH is a leading provider of online dating products and services. The company owns and operates a diverse portfolio of consumer brands that connect singles through digital platforms. Its flagship offerings include Match.com, Tinder, Hinge, OkCupid and PlentyOfFish, which together serve users looking for long-term relationships, casual encounters and social networking opportunities.

Originating with the launch of Match.com in 1995, Match Group has grown through a combination of organic development and strategic acquisitions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].

Should You Invest $1,000 in Match Group Right Now?Before you consider Match Group, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Match Group wasn't on the list.

While Match Group currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

New campaign features global-inspired recipes, a multi-city food truck tour, creator collaborations, a sweepstakes and more, inspired by the summer's biggest soccer tournament

, /PRNewswire/ -- As soccer fans around the world gather to cheer on their favorite teams this summer, TUMS is bringing fans together over another shared passion: food. An extension of Haleon's partnership with U.S. Soccer, TUMS has announced the launch of the "TUMS Food Match Cup," a first-of-its-kind campaign inspired by the global flavors, traditions and team passions that make soccer's biggest tournament season unforgettable. From bold culinary mashups and creator collaborations to immersive fan experiences and daily sweepstakes, the TUMS Food Match Cup celebrates the intersection of soccer fandom, food culture and fast-acting heartburn relief — helping fans stay focused on the action, not their symptoms.

TUMS Food Match Cup logo

TUMS Food Match Cup "Soccer's biggest moments bring fans from around the world together, and food is often at the center of those celebrations — whether it's spicy street tacos, grilled favorites or comforting classics shared while cheering on your team," said Patricia Melo, Brand Director for TUMS. "With the TUMS Food Match Cup, we wanted to celebrate that sense of global unity through original recipe mashups inspired by countries competing on the pitch, combining iconic flavors and dishes from around the world into unexpected, crave-worthy creations, all paired with trusted heartburn relief that helps fans stay focused on the celebration."

Featured dishes include:

The Plantain Dog, a sweet-and-savory fusion inspired by flavors from the USA and Paraguay Kimchi Carnitas Tacos, blending Korean and Mexican culinary traditions Raclette Poutine, combining Swiss alpine comfort food with a Canadian classic Throughout the tournament, fans can visit TUMSFoodMatchCup.com to spin the daily wheel for a chance to unlock a new recipe mashup inspired by competing countries and their signature cuisines, along with a recommended TUMS product pairing. Fans can also enter daily for a chance to win prizes, including U.S. Soccer merchandise, special savings offers from TUMS and the grand prize: a $200 Ticketmaster e-gift card that can be used toward U.S. Soccer tickets.

The campaign will also be amplified through additional creator partnerships, including a partnership with chef, creator and cookbook author Joshua Weissman.

"To me, food and soccer have this incredible ability to bring people together and spark a sense of connection and creativity," said Joshua Weissman. "Working with TUMS on the Food Match Cup gave me the chance to help celebrate unexpected flavors and culinary traditions in a way that encompasses the energy and excitement that fans are feeling all summer long."

TUMS is also bringing the campaign directly to fans through the Food Match Cup Food Truck Tour, a multi-city experience designed to celebrate the excitement of match day through globally inspired flavors and interactive fan engagement. The tour will stop in Los Angeles, Houston, Kansas City, Dallas and New York City, making 14 stops at retail locations, including Walmart and Kroger, as well as the Gameday Goal Zone Pre-Match Hospitality event at MetLife Stadium.

Visitors can sample tournament-inspired dishes from the TUMS food truck, capture memories through interactive photo opportunities, enjoy giveaways and receive TUMS samples and products — all designed to help ensure heartburn doesn't interrupt the excitement of game day.

Fans can follow along throughout the tournament to discover new recipe mashups, enter the sweepstakes and find upcoming tour stops at TUMSFoodMatchCup.com and on @TUMSOfficial across Instagram and TikTok.

About TUMS
TUMS is the #1 recommended antacid brand by doctors, pharmacists and OBGYNs. As America's #1 antacid brand, TUMS offers a wide variety of flavors and formats with something for everyone. TUMS Chewy Bites provide tasty, effective multi-symptom relief from heartburn, sour stomach, acid indigestion and upset stomach so you can savor the moment. TUMS Gummy Bites go to work in seconds* for occasional heartburn relief and feature a soft, easy-to-chew format with multi-benefit relief from occasional sour stomach, acid indigestion and upset stomach.

*These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure or prevent any disease.

About Haleon
Haleon (LSE/NYSE: HLN) is a globally leading consumer company that is solely focused on better everyday health. Haleon's product portfolio spans three major categories - Oral Health, Over-the-Counter (OTC), and Wellness. Its long-standing brands - such as Advil, Centrum, Parodontax, Sensodyne, Theraflu, and TUMS - are built on trusted science, innovation and deep human understanding. For more information on Haleon and its brands, please visit www.haleon.com or contact [email protected].

SOURCE TUMS